| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 15 | 2025 | 191 | 4.150 |
Why?
|
| Medulloblastoma | 23 | 2024 | 325 | 3.380 |
Why?
|
| Cerebellar Neoplasms | 21 | 2024 | 275 | 3.260 |
Why?
|
| Proton Therapy | 22 | 2024 | 123 | 3.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 | 2020 | 783 | 2.670 |
Why?
|
| Craniospinal Irradiation | 10 | 2023 | 58 | 2.020 |
Why?
|
| Cancer Survivors | 15 | 2024 | 211 | 1.950 |
Why?
|
| Brain Neoplasms | 26 | 2024 | 1214 | 1.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 1254 | 1.890 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 5 | 2024 | 51 | 1.540 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 121 | 1.500 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1143 | 1.430 |
Why?
|
| Child | 114 | 2025 | 24384 | 1.340 |
Why?
|
| Child, Preschool | 76 | 2025 | 14005 | 1.210 |
Why?
|
| Polymorphism, Genetic | 6 | 2011 | 816 | 1.110 |
Why?
|
| Photons | 5 | 2021 | 48 | 1.070 |
Why?
|
| Glioma | 10 | 2024 | 489 | 1.000 |
Why?
|
| Adolescent | 80 | 2025 | 19351 | 0.990 |
Why?
|
| Survivors | 20 | 2024 | 339 | 0.980 |
Why?
|
| Pituitary Neoplasms | 5 | 2023 | 80 | 0.960 |
Why?
|
| Nocardia Infections | 1 | 2024 | 14 | 0.880 |
Why?
|
| Infant | 46 | 2025 | 12476 | 0.870 |
Why?
|
| Salvage Therapy | 2 | 2024 | 192 | 0.870 |
Why?
|
| Neoplasms | 17 | 2024 | 2792 | 0.870 |
Why?
|
| Fibroma | 1 | 2022 | 29 | 0.790 |
Why?
|
| Sarcoma | 2 | 2022 | 182 | 0.780 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2023 | 197 | 0.750 |
Why?
|
| Humans | 141 | 2025 | 125086 | 0.740 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 67 | 0.740 |
Why?
|
| Female | 104 | 2025 | 66747 | 0.720 |
Why?
|
| Male | 100 | 2025 | 61463 | 0.720 |
Why?
|
| Glutathione Transferase | 5 | 2013 | 155 | 0.710 |
Why?
|
| Hearing Loss | 4 | 2024 | 135 | 0.680 |
Why?
|
| Diagnostic Imaging | 3 | 2022 | 277 | 0.680 |
Why?
|
| Sarcoma, Synovial | 4 | 2024 | 21 | 0.660 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2017 | 70 | 0.650 |
Why?
|
| Head and Neck Neoplasms | 7 | 2021 | 503 | 0.650 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2023 | 3156 | 0.650 |
Why?
|
| Scoliosis | 1 | 2021 | 135 | 0.640 |
Why?
|
| Genotype | 13 | 2016 | 2561 | 0.630 |
Why?
|
| Birth Weight | 5 | 2015 | 345 | 0.620 |
Why?
|
| Cisplatin | 7 | 2024 | 249 | 0.600 |
Why?
|
| Retrospective Studies | 42 | 2024 | 16326 | 0.590 |
Why?
|
| Ependymoma | 6 | 2023 | 125 | 0.570 |
Why?
|
| Protons | 8 | 2023 | 92 | 0.550 |
Why?
|
| Radiotherapy Dosage | 12 | 2023 | 183 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2020 | 2633 | 0.530 |
Why?
|
| Cognition | 8 | 2023 | 731 | 0.520 |
Why?
|
| Prognosis | 19 | 2025 | 4638 | 0.520 |
Why?
|
| Biomarkers, Tumor | 9 | 2025 | 1498 | 0.510 |
Why?
|
| Radiotherapy | 3 | 2014 | 135 | 0.500 |
Why?
|
| Survivorship | 4 | 2024 | 36 | 0.500 |
Why?
|
| Cognition Disorders | 7 | 2017 | 553 | 0.500 |
Why?
|
| Neoplasm, Residual | 5 | 2013 | 122 | 0.490 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2012 | 25 | 0.480 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 1241 | 0.470 |
Why?
|
| Carcinoma | 1 | 2017 | 287 | 0.470 |
Why?
|
| Craniopharyngioma | 4 | 2023 | 33 | 0.460 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 899 | 0.460 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 70 | 0.450 |
Why?
|
| Antineoplastic Agents | 13 | 2024 | 1695 | 0.450 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 450 | 0.440 |
Why?
|
| Follow-Up Studies | 16 | 2024 | 5175 | 0.440 |
Why?
|
| Cost Savings | 1 | 2014 | 71 | 0.430 |
Why?
|
| Risk Factors | 19 | 2024 | 10284 | 0.420 |
Why?
|
| Proportional Hazards Models | 10 | 2025 | 1357 | 0.410 |
Why?
|
| Mutism | 2 | 2024 | 28 | 0.410 |
Why?
|
| Adult | 35 | 2024 | 29632 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2021 | 1054 | 0.400 |
Why?
|
| DNA Methylation | 5 | 2020 | 1008 | 0.400 |
Why?
|
| Folic Acid | 2 | 2012 | 294 | 0.390 |
Why?
|
| Quality of Health Care | 1 | 2015 | 391 | 0.390 |
Why?
|
| Ambulatory Care | 1 | 2015 | 389 | 0.390 |
Why?
|
| Bone Marrow | 2 | 2021 | 325 | 0.380 |
Why?
|
| Young Adult | 20 | 2024 | 9052 | 0.380 |
Why?
|
| Neuroblastoma | 5 | 2010 | 524 | 0.380 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 128 | 0.360 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 136 | 0.360 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 3 | 2021 | 36 | 0.360 |
Why?
|
| Radiation Injuries | 7 | 2021 | 142 | 0.350 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 187 | 0.340 |
Why?
|
| Attention | 3 | 2019 | 202 | 0.340 |
Why?
|
| Intelligence | 3 | 2023 | 98 | 0.330 |
Why?
|
| Body Height | 1 | 2010 | 215 | 0.320 |
Why?
|
| Models, Genetic | 2 | 2014 | 760 | 0.310 |
Why?
|
| Hypothyroidism | 2 | 2021 | 90 | 0.310 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 224 | 0.310 |
Why?
|
| Cochlea | 2 | 2024 | 85 | 0.310 |
Why?
|
| Survival Rate | 8 | 2024 | 2061 | 0.300 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 13 | 0.290 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NAD+) | 1 | 2007 | 3 | 0.290 |
Why?
|
| Genetic Markers | 3 | 2015 | 603 | 0.280 |
Why?
|
| Hodgkin Disease | 2 | 2024 | 294 | 0.270 |
Why?
|
| Disease Progression | 6 | 2023 | 2062 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2022 | 546 | 0.260 |
Why?
|
| Case-Control Studies | 12 | 2015 | 3299 | 0.250 |
Why?
|
| Bone Neoplasms | 3 | 2022 | 425 | 0.240 |
Why?
|
| Texas | 11 | 2023 | 3587 | 0.230 |
Why?
|
| Osteosarcoma | 2 | 2022 | 255 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 97 | 0.230 |
Why?
|
| Margins of Excision | 1 | 2024 | 51 | 0.230 |
Why?
|
| Aftercare | 2 | 2017 | 148 | 0.220 |
Why?
|
| Repressor Proteins | 2 | 2022 | 815 | 0.220 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 163 | 0.220 |
Why?
|
| Intelligence Tests | 3 | 2022 | 57 | 0.220 |
Why?
|
| Isoenzymes | 1 | 2004 | 231 | 0.210 |
Why?
|
| Menorrhagia | 1 | 2024 | 75 | 0.210 |
Why?
|
| Germinoma | 1 | 2023 | 30 | 0.210 |
Why?
|
| Algorithms | 2 | 2024 | 1629 | 0.210 |
Why?
|
| Medical Oncology | 3 | 2011 | 215 | 0.210 |
Why?
|
| Leuprolide | 1 | 2023 | 22 | 0.210 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 11 | 0.210 |
Why?
|
| Obesity | 3 | 2020 | 2247 | 0.210 |
Why?
|
| Vincristine | 4 | 2021 | 193 | 0.200 |
Why?
|
| Epoxide Hydrolases | 2 | 2013 | 37 | 0.200 |
Why?
|
| Treatment Outcome | 15 | 2023 | 12391 | 0.200 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 238 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 118 | 0.200 |
Why?
|
| Tracheostomy | 1 | 2024 | 192 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2021 | 100 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2012 | 50 | 0.190 |
Why?
|
| Xerostomia | 1 | 2021 | 7 | 0.190 |
Why?
|
| Tooth Abnormalities | 1 | 2021 | 9 | 0.190 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 73 | 0.190 |
Why?
|
| Fever | 1 | 2024 | 298 | 0.180 |
Why?
|
| Salivary Glands | 1 | 2021 | 33 | 0.180 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1437 | 0.180 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 28 | 0.180 |
Why?
|
| Drug Costs | 1 | 2021 | 61 | 0.180 |
Why?
|
| Cyclophosphamide | 3 | 2021 | 417 | 0.180 |
Why?
|
| Paresis | 1 | 2021 | 35 | 0.180 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 21 | 0.180 |
Why?
|
| Caregivers | 2 | 2023 | 575 | 0.180 |
Why?
|
| Hemiplegia | 1 | 2021 | 45 | 0.180 |
Why?
|
| Granuloma, Giant Cell | 1 | 2020 | 13 | 0.180 |
Why?
|
| Denosumab | 1 | 2020 | 13 | 0.180 |
Why?
|
| Sarcoma, Ewing | 1 | 2022 | 110 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 174 | 0.180 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 107 | 0.170 |
Why?
|
| Neuropsychological Tests | 6 | 2024 | 925 | 0.170 |
Why?
|
| Dactinomycin | 2 | 2021 | 66 | 0.170 |
Why?
|
| Bone Density Conservation Agents | 1 | 2020 | 52 | 0.170 |
Why?
|
| Iron | 1 | 2022 | 270 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2023 | 144 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 651 | 0.160 |
Why?
|
| Carboplatin | 2 | 2017 | 76 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1065 | 0.160 |
Why?
|
| Incidence | 3 | 2022 | 3140 | 0.160 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 60 | 0.160 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 67 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 293 | 0.160 |
Why?
|
| Neurosurgical Procedures | 2 | 2023 | 302 | 0.160 |
Why?
|
| Infant, Newborn | 7 | 2017 | 8202 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2015 | 1501 | 0.150 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1525 | 0.150 |
Why?
|
| Treatment Failure | 5 | 2021 | 340 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 140 | 0.150 |
Why?
|
| Glioblastoma | 4 | 2006 | 330 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 190 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 142 | 0.150 |
Why?
|
| Radiotherapy, Conformal | 2 | 2008 | 55 | 0.150 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2018 | 10 | 0.150 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3071 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 557 | 0.140 |
Why?
|
| Metabolomics | 1 | 2021 | 423 | 0.140 |
Why?
|
| Morbidity | 3 | 2024 | 248 | 0.140 |
Why?
|
| Human Growth Hormone | 1 | 1998 | 74 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 1584 | 0.140 |
Why?
|
| Cushing Syndrome | 1 | 2017 | 16 | 0.140 |
Why?
|
| Superoxide Dismutase | 2 | 2015 | 185 | 0.140 |
Why?
|
| Leucovorin | 1 | 2017 | 49 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2020 | 1563 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 405 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 57 | 0.140 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 1275 | 0.140 |
Why?
|
| Brain Stem | 2 | 2015 | 115 | 0.140 |
Why?
|
| Fluorouracil | 1 | 2017 | 128 | 0.140 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 17 | 0.130 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 18 | 0.130 |
Why?
|
| Registries | 3 | 2019 | 1432 | 0.130 |
Why?
|
| Hyperglycemia | 2 | 2009 | 225 | 0.130 |
Why?
|
| Logistic Models | 3 | 2010 | 1809 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1998 | 140 | 0.130 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 21 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Age Factors | 5 | 2024 | 2817 | 0.130 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 303 | 0.130 |
Why?
|
| Executive Function | 1 | 2017 | 110 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 54 | 0.130 |
Why?
|
| United States | 6 | 2022 | 10912 | 0.130 |
Why?
|
| Growth Disorders | 1 | 1998 | 209 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2015 | 1256 | 0.120 |
Why?
|
| Recurrence | 3 | 2023 | 1421 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 986 | 0.120 |
Why?
|
| Ear Diseases | 1 | 2015 | 18 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2015 | 13 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 575 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2015 | 36 | 0.120 |
Why?
|
| Brain | 4 | 2023 | 2999 | 0.120 |
Why?
|
| Bone Marrow Examination | 2 | 2005 | 14 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2015 | 210 | 0.120 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 22 | 0.120 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 5 | 0.120 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 671 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 128 | 0.110 |
Why?
|
| Survival Analysis | 5 | 2008 | 1506 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 2014 | 46 | 0.110 |
Why?
|
| Health Services | 1 | 2014 | 71 | 0.110 |
Why?
|
| Filgrastim | 1 | 2014 | 15 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 50 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1547 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 468 | 0.110 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 95 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 253 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 96 | 0.110 |
Why?
|
| Infant Food | 1 | 2013 | 81 | 0.110 |
Why?
|
| Teratoma | 1 | 2014 | 120 | 0.110 |
Why?
|
| Leukemia | 2 | 2010 | 371 | 0.110 |
Why?
|
| Amifostine | 2 | 2010 | 14 | 0.110 |
Why?
|
| Overweight | 1 | 2016 | 364 | 0.110 |
Why?
|
| Consensus | 1 | 2016 | 641 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 275 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 42 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2015 | 489 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 423 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3081 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2426 | 0.100 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2012 | 11 | 0.100 |
Why?
|
| Air Pollutants, Occupational | 1 | 2012 | 18 | 0.100 |
Why?
|
| Telomere | 1 | 2013 | 213 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 152 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 369 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 184 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1696 | 0.100 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 1684 | 0.090 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2011 | 21 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2021 | 6154 | 0.090 |
Why?
|
| Haplotypes | 1 | 2013 | 522 | 0.090 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 121 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 190 | 0.090 |
Why?
|
| Inpatients | 1 | 2015 | 499 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 94 | 0.090 |
Why?
|
| Liposarcoma | 1 | 2011 | 22 | 0.090 |
Why?
|
| Time Factors | 4 | 2024 | 6327 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 651 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 290 | 0.090 |
Why?
|
| Vaccination | 1 | 2016 | 961 | 0.090 |
Why?
|
| Social Adjustment | 2 | 2022 | 84 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Chemokines, CXC | 1 | 2010 | 38 | 0.090 |
Why?
|
| Nervous System Diseases | 3 | 2013 | 375 | 0.090 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 22 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2015 | 769 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2012 | 102 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1399 | 0.080 |
Why?
|
| Gestational Age | 2 | 2015 | 1161 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2014 | 3456 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 686 | 0.080 |
Why?
|
| Fetal Macrosomia | 1 | 2010 | 20 | 0.080 |
Why?
|
| Pediatrics | 2 | 2011 | 1149 | 0.080 |
Why?
|
| Prodrugs | 1 | 2010 | 59 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 369 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 186 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 95 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2021 | 230 | 0.080 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2009 | 23 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 3570 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1098 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 237 | 0.080 |
Why?
|
| Oligodendroglioma | 2 | 2010 | 22 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 763 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1267 | 0.080 |
Why?
|
| Astrocytoma | 2 | 2013 | 99 | 0.080 |
Why?
|
| Parents | 2 | 2023 | 1026 | 0.080 |
Why?
|
| Carmustine | 2 | 1999 | 26 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2011 | 396 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2009 | 71 | 0.080 |
Why?
|
| Middle Aged | 9 | 2024 | 26926 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 294 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 3728 | 0.070 |
Why?
|
| Cyclins | 2 | 1999 | 101 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 504 | 0.070 |
Why?
|
| Quality of Life | 3 | 2023 | 1939 | 0.070 |
Why?
|
| Neutropenia | 1 | 2009 | 200 | 0.070 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 16 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2013 | 306 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 226 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2024 | 643 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2009 | 313 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 3423 | 0.070 |
Why?
|
| Syndrome | 2 | 2022 | 1120 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1662 | 0.070 |
Why?
|
| Radiation Oncology | 1 | 2007 | 23 | 0.070 |
Why?
|
| Remission Induction | 2 | 2008 | 300 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 196 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2007 | 184 | 0.060 |
Why?
|
| Hospitalization | 1 | 2014 | 1779 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 755 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 723 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 519 | 0.060 |
Why?
|
| Apoptosis | 5 | 2010 | 1805 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 363 | 0.060 |
Why?
|
| Vision Disorders | 2 | 2021 | 211 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2005 | 794 | 0.060 |
Why?
|
| Methotrexate | 1 | 2007 | 337 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 160 | 0.060 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 22 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 2169 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2012 | 826 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 330 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2019 | 4814 | 0.060 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2004 | 23 | 0.060 |
Why?
|
| Age Distribution | 2 | 2002 | 417 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 56 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 144 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 63 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 103 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2054 | 0.050 |
Why?
|
| Genomics | 1 | 2011 | 1502 | 0.050 |
Why?
|
| Linear Models | 2 | 2016 | 680 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2003 | 33 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 369 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2005 | 432 | 0.050 |
Why?
|
| Tennessee | 1 | 2003 | 27 | 0.050 |
Why?
|
| Italy | 1 | 2003 | 100 | 0.050 |
Why?
|
| Germany | 1 | 2003 | 65 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 37 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 613 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 66 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 187 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 272 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 442 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2002 | 285 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 321 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 464 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 331 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2025 | 319 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2023 | 302 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 2009 | 2820 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 417 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2022 | 310 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 341 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 779 | 0.050 |
Why?
|
| Emotions | 1 | 2024 | 358 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2021 | 150 | 0.050 |
Why?
|
| Reoperation | 1 | 2024 | 833 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 715 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 31 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 438 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2906 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 1020 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 526 | 0.040 |
Why?
|
| Research | 1 | 2022 | 262 | 0.040 |
Why?
|
| Alleles | 2 | 2015 | 1616 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2002 | 388 | 0.040 |
Why?
|
| Proctitis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 1999 | 85 | 0.040 |
Why?
|
| Tretinoin | 1 | 1999 | 117 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 1999 | 7 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 190 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2019 | 70 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 509 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 3349 | 0.040 |
Why?
|
| Cystectomy | 1 | 2019 | 160 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 870 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 250 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 224 | 0.040 |
Why?
|
| Lymphatic Irradiation | 1 | 2018 | 5 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 6 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 182 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 48 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 1999 | 174 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2019 | 344 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 2047 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 479 | 0.040 |
Why?
|
| Pregnancy | 3 | 2015 | 7194 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 4 | 1999 | 1064 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 410 | 0.030 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 87 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 411 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 810 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 74 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 381 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2021 | 816 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 2452 | 0.030 |
Why?
|
| Appendectomy | 1 | 2017 | 86 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 126 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 135 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 379 | 0.030 |
Why?
|
| Aged | 5 | 2014 | 19861 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1328 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 86 | 0.030 |
Why?
|
| Appendicitis | 1 | 2017 | 128 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 540 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 324 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 55 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 200 | 0.030 |
Why?
|
| Hospital Records | 1 | 2014 | 8 | 0.030 |
Why?
|
| Birth Order | 1 | 2014 | 7 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1398 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2009 | 1133 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 64 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 299 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2010 | 290 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 134 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 474 | 0.030 |
Why?
|
| DNA Repair | 2 | 2012 | 585 | 0.030 |
Why?
|
| Xenobiotics | 1 | 2013 | 26 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 245 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 43 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 59 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 821 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1331 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1287 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2312 | 0.030 |
Why?
|
| Infant Formula | 1 | 2013 | 96 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 81 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 2890 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 339 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 869 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 206 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 724 | 0.020 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 29 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 55 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 192 | 0.020 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2012 | 10 | 0.020 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2012 | 14 | 0.020 |
Why?
|
| Solvents | 1 | 2012 | 45 | 0.020 |
Why?
|
| Consent Forms | 1 | 2011 | 22 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2010 | 1632 | 0.020 |
Why?
|
| Melanoma | 1 | 1999 | 944 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 255 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1894 | 0.020 |
Why?
|
| Genetic Privacy | 1 | 2011 | 42 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 5848 | 0.020 |
Why?
|
| Poliovirus Vaccines | 1 | 2011 | 14 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 237 | 0.020 |
Why?
|
| Haemophilus Vaccines | 1 | 2011 | 30 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 725 | 0.020 |
Why?
|
| Premature Birth | 1 | 2015 | 384 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 590 | 0.020 |
Why?
|
| Chemokine CXCL6 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 42 | 0.020 |
Why?
|
| Platelet Factor 4 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 36 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 512 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 137 | 0.020 |
Why?
|
| Mercaptoethylamines | 1 | 2010 | 1 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2010 | 24 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 20 | 0.020 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2009 | 26 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2009 | 32 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 175 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 6597 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2009 | 27 | 0.020 |
Why?
|
| Benzazepines | 1 | 2009 | 62 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 513 | 0.020 |
Why?
|
| Asparaginase | 1 | 2009 | 41 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 779 | 0.020 |
Why?
|
| Informed Consent | 1 | 2011 | 333 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1999 | 81 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 276 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2011 | 350 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 65 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1893 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 701 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 592 | 0.020 |
Why?
|
| Child Advocacy | 1 | 2007 | 10 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2009 | 279 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2007 | 62 | 0.020 |
Why?
|
| Down-Regulation | 2 | 1999 | 698 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 382 | 0.020 |
Why?
|
| Vaccines | 1 | 2011 | 367 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 154 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1236 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2005 | 112 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 1274 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 32 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 2004 | 38 | 0.010 |
Why?
|
| Epilepsy | 1 | 2011 | 874 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2009 | 985 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 785 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2001 | 97 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 1999 | 4 | 0.010 |
Why?
|
| Phosphoserine | 1 | 1999 | 41 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 31 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 71 | 0.010 |
Why?
|
| Cytarabine | 1 | 1999 | 98 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1999 | 108 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 33 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 92 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 173 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1999 | 244 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 462 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1999 | 230 | 0.010 |
Why?
|
| Doxycycline | 1 | 1998 | 117 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 241 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 699 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 506 | 0.010 |
Why?
|
| Acute Disease | 1 | 1999 | 1110 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 1290 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 1068 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1999 | 604 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1999 | 937 | 0.010 |
Why?
|
| Gene Expression | 1 | 1999 | 1561 | 0.010 |
Why?
|
| DNA Damage | 1 | 1998 | 513 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1999 | 1024 | 0.010 |
Why?
|